Company Overview and News
SANTA CLARA, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today announced it has been placed in the Leaders category of the International Data Corporation (IDC) MarketScape: Worldwide Object-based Storage 2018 Vendor Assessment (DOC # US42665518, June 2018) based on its Hitachi Content Platform solution.
Here we are with another installment of my "stock considerations" for the upcoming month. With the first week of trading upon us in July, it is time, once again, to lay out a plan for my potential stock pick(s) for the month. As many of you already know, I make sure to purchase at least one stock every single month, no matter where we are in a business or macroeconomic cycle. The goal of every long-term dividend growth investor is to remain consistent with their buys and try not to attempt to time the market and wait for the "best" possible time to invest.
SOJA HCN PM GIS HCP WELL.PRI LTC SBRA WELL CAH ED JCI SBRAP VTR SO GE GEC D HCN.PRJ KMB HCN.PRI PEP KHC GNE SBUX CLX
HCP Inc. (HCP - Free Report) is rumored to be selling the company’s 22 Brookdale-managed senior housing properties for $428 million to New York firm — Apollo Global Management LLC (APO - Free Report) — per a Bloomberg news. Earlier this June, the company announced that it has entered into definitive deals for selling those 22 properties, having 2,781 units, to an institutional investor. This healthcare REIT has been selling several of its senior housing assets in a bid to improve the quality of the company’s senior housing portfolio, strengthen balance sheet and lower the Brookdale Senior Living Inc.
PLD APO.PRB HFC APO.PRA HCP BKD APO EXR
HCP Inc. (HCP - Free Report) has undertaken portfolio-repositioning measures in a bid to improve the quality of its senior housing portfolio and lower the concentration of Brookdale Senior Living Inc. Earlier in this month, HCP provided an update about such efforts and it seems right on track to achieve its target. In fact, over time, with diligent measures, the company aims at having more than half of its business comprising specialty office segments of medical office and life science, and lower senior housing concentration to around 40%.
LHO TRNO.PRA ABR HCP BKD ABRN TRNO ABRN.CL LHO.PRG LHO.PRJ ABR.PRB ABR.PRC LHO.PRI ABR.PRA LHO.PRH
HCP Inc. (HCP - Free Report) has undertaken strategic portfolio-repositioning measures in a bid to improve the quality of its senior housing portfolio and lower the Brookdale Senior Living Inc. operator concentration. The company, recently, provided an update about such efforts and it seems right on track to achieve its target. Particularly, HCP has reaped $332 million of proceeds through completion of the disposition of its residual investment in the RIDEA II senior housing joint venture (JV) to an investor group led by Columbia Pacific Advisors, LLC.
PLD HCP BKD EXR
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to HCP / HCP, Inc. on message board site Silicon Investor.
|United Heritage (UHCP)|
as of ET